UBS analyst David Dai initiated coverage of Kura Oncology (KURA) with a Buy rating and $27 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Kura has a “highly efficacious and safe” menin therapy in acute myeloid leukemia which supports front-line use long-term, the analyst tells investors in a research note.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology presents new data on KO-2806 with targeted therapies
- Kura Oncology initiated with an Outperform at LifeSci Capital
- Kura Oncology downgraded to Hold from Buy at Stifel
- Kura Oncology announces Ziftomenib Phase 1 results in The Lancet
- Kura Oncology Welcomes New Director Michael Vasconcelles